Table 1

Eight cases of Rothia mucilaginosa prosthetic device infections reported in the literature and our case

ReferenceAge of patient (yrs)SexUnderlying diseases/risk factorsDiagnosisAntibiotic therapyaSurgical therapyComplicationsOutcome
735MProsthetic aortic valve replacement/intravenous drug userProsthetic heart valve endocarditisVancomycin i.v. plus gentamicin i.v. for 4 wks then vancomycin i.v. for 4 wks after surgeryValve replacementRight leg weakness (left parietal lobe infarction)Survived
829MBioprosthetic aortic valve replacement/intravenous drug userProsthetic heart valve endocarditisVancomycin i.v. plus gentamicin i.v. plus rifampin p.o.NoneTransient episodes of weakness on hospital day 4Expired on hospital day 6
933MProsthetic mitral valve replacement/intravenous drug userProsthetic heart valve endocarditisVancomycin i.v. for 4 wksValve replacementNoneSurvived
1749MEnd-stage renal disease, continuous ambulatory peritoneal dialysisPeritoneal dialysis catheter-related peritonitisAmoxicillin p.o. plus rifampin p.o. (duration not reported)Not reportedNoneSurvived
1852FBioprosthetic aortic and mitral valve replacement/intravenous drug userProsthetic heart valve endocarditisPenicillin G for 6 wks plus rifampin p.o. followed by ampicillin i.v. plus rifampin p.o. for 2 wksNoneNoneExpired after 8-wk course of antibiotic therapy
1821MRelapsed acute lymphocytic leukemia, Ommaya reservoir for intrathecal chemotherapyIntraventricular catheter-related ventriculitisVancomycin i.v. plus rifampin p.o. for 2 wks plus intrathecal vancomycin for 5 daysOmmaya reservoir removalNoneSurvived
1959MTotal hip arthroplastyLate prosthetic joint infectionVancomycin i.v. for 12 wksPartial hip revision followed by 2-stage revisionNoneSurvived
Our case36MMechanical mitral valve replacement/intravenous drug userProsthetic heart valve endocarditisVancomycin i.v. for 6 wksValve replacementLower-extremity arterial thrombus/embolusSurvived
  • a i.v., intravenously; p.o., per os.